Premium
MALDI imaging mass spectrometry reveals multiple clinically relevant masses in colorectal cancer using large‐scale tissue microarrays
Author(s) -
Hinsch A.,
Buchholz M.,
Odinga S.,
Borkowski C.,
Koop C.,
Izbicki J. R.,
Wurlitzer M.,
Krech T.,
Wilczak W.,
Steurer S.,
Jacobsen F.,
Burandt E.C.,
Stahl P.,
Simon R.,
Sauter G.,
Schlüter H.
Publication year - 2017
Publication title -
journal of mass spectrometry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.475
H-Index - 121
eISSN - 1096-9888
pISSN - 1076-5174
DOI - 10.1002/jms.3916
Subject(s) - mass spectrometry imaging , chemistry , maldi imaging , mass spectrometry , tissue microarray , colorectal cancer , univariate analysis , matrix assisted laser desorption/ionization , pathology , cancer , medicine , multivariate analysis , chromatography , desorption , organic chemistry , adsorption
For identification of clinically relevant masses to predict status, grade, relapse and prognosis of colorectal cancer, we applied Matrix‐assisted laser desorption ionization (MALDI) imaging mass spectrometry (IMS) to a tissue micro array containing formalin‐fixed and paraffin‐embedded tissue samples from 349 patients. Analysis of our MALDI‐IMS data revealed 27 different m/z signals associated with epithelial structures. Comparison of these signals showed significant association with status, grade and Ki‐67 labeling index. Fifteen out of 27 IMS signals revealed a significant association with survival. For seven signals ( m/z 654, 776, 788, 904, 944, 975 and 1013) the absence and for eight signals ( m/z 643, 678, 836, 886, 898, 1095, 1459 and 1477) the presence were associated with decreased life expectancy, including five masses ( m/z 788, 836, 904, 944 and 1013) that provided prognostic information independently from the established prognosticators pT and pN. Combination of these five masses resulted in a three‐step classifier that provided prognostic information superior to univariate analysis. In addition, a total of 19 masses were associated with tumor stage, grade, metastasis and cell proliferation. Our data demonstrate the suitability of combining IMS and large‐scale tissue micro arrays to simultaneously identify and validate clinically useful molecular marker. Copyright © 2017 John Wiley & Sons, Ltd.